Investigational Drug Information for INCB050465
✉ Email this page to a colleague
What is the drug development status for INCB050465?
INCB050465 is an investigational drug.
There have been 32 clinical trials for INCB050465.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Lymphoma, Follicular. The leading clinical trial sponsors are Incyte Corporation, Mayo Clinic, and Incyte Biosciences Japan GK.
There are ten US patents protecting this investigational drug and two hundred and eighty-two international patents.
Summary for INCB050465
| US Patents | 10 |
| International Patents | 282 |
| US Patent Applications | 61 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 2 (2022-02-01) |
| Vendors | 32 |
Recent Clinical Trials for INCB050465
| Title | Sponsor | Phase |
|---|---|---|
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | Incyte Corporation | Phase 3 |
| Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | Incyte Corporation | Phase 3 |
| IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. | Chinese PLA General Hospital | Phase 2 |
Clinical Trial Summary for INCB050465
Top disease conditions for INCB050465
Top clinical trial sponsors for INCB050465
US Patents for INCB050465
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INCB050465 | ⤷ Subscribe | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| INCB050465 | ⤷ Subscribe | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| INCB050465 | ⤷ Subscribe | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| INCB050465 | ⤷ Subscribe | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| INCB050465 | ⤷ Subscribe | Salts and processes of preparing a PI3K inhibitor | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| INCB050465 | ⤷ Subscribe | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| INCB050465 | ⤷ Subscribe | Heterocyclic compounds as immunomodulators | Incyte Corporation (Wilmington, DE) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INCB050465
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INCB050465 | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Subscribe |
| INCB050465 | World Intellectual Property Organization (WIPO) | WO2017035366 | 2035-08-26 | ⤷ Subscribe |
| INCB050465 | Australia | AU2015244044 | 2034-04-08 | ⤷ Subscribe |
| INCB050465 | Australia | AU2020213313 | 2034-04-08 | ⤷ Subscribe |
| INCB050465 | Australia | AU2022206693 | 2034-04-08 | ⤷ Subscribe |
| INCB050465 | Brazil | BR112016023322 | 2034-04-08 | ⤷ Subscribe |
| INCB050465 | Brazil | BR122021024771 | 2034-04-08 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
